{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-134303","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.116483+00:00","generated_at":"2026-06-02T09:10:14.595005+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Catalyst Q1 revenue $98.5M (+15.4% YoY); AGAMREE launch adds $1.2M","bullets":["Total Q1 2024 net product revenue $98.5M, up 15.4% YoY; FIRDAPSE net revenue $66.8M (+16.2%).","AGAMREE contributed $1.2M net revenue in first two weeks of U.S. launch, surpassing initial expectations.","GAAP net income $23.3M ($0.19 diluted EPS); Non-GAAP net income $46.8M ($0.38 diluted EPS).","Cash and cash equivalents $310.4M as of March 31, 2024, a 125.5% increase from year-end 2023.","Full-year 2024 total revenue guidance reaffirmed at $455M-$475M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-134303","json":"https://secwatch.observer/filing/0001193125-24-134303.json","markdown":"https://secwatch.observer/filing/0001193125-24-134303.md","text":"https://secwatch.observer/filing/0001193125-24-134303.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312524134303/0001193125-24-134303-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312524134303/d837068d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:10:14.595005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}